Drugs / OCIFISERTIB
OCIFISERTIB
also known as
CFI-400945 · AK173721 · AKOS025396133 · CFI-400945 (FREE BASE) · CFI-400945 FUMARATE · Ocifisertib fumarate · OCIFISERTIB(CFI-400945 FREE BASE)
Small molecule targets PLK4 via inhibition
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03187288 | May 2018 → Jun 2021 | acute myeloid leukemia, myelodysplastic syndrome, refractory malignant neoplasm | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT01954316 | Mar 2014 → Jul 2021 | cancer of unknown primary site | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04730258 | Apr 2021 → Jan 2026 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Treadwell Therapeutics, Inc | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05601440 | Jun 2023 → Dec 2027 expected | female breast carcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT04176848 | Aug 2020 → Sep 2022 overdue | breast cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03624543 | Feb 2019 → Jun 2026 overdue | breast cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03385655 | Aug 2018 → Oct 2024 overdue | prostate cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCIFISERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3408947 ↗ |
| Known as | AK173721 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3408947 ↗ |
| Known as | AKOS025396133 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3408947 ↗ |
| Known as | CFI-400945 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03624543 ↗ |
| Known as | CFI-400945 (FREE BASE) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3408947 ↗ |
| Known as | CFI-400945 FUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3408947 ↗ |
| Known as | Ocifisertib fumarate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3408947 ↗ |
| Known as | OCIFISERTIB(CFI-400945 FREE BASE) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3408947 ↗ |
| Action | Inhibit | “blocking polo-like kinase 4 (PLK4) from working” NCT01954316 ↗ |
| Modality | Small molecule | — CHEMBL3408947 ↗ |
| Route | Oral | “CFI-400945 is an oral (taken by mouth) drug” NCT01954316 ↗ |
| Target | PLK4 | “blocking polo-like kinase 4 (PLK4) from working” NCT01954316 ↗ |